BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 36826096)

  • 1. Management of Marginal Zone Lymphoma: A Canadian Perspective.
    Peters A; Keating MM; Nikonova A; Doucette S; Prica A
    Curr Oncol; 2023 Feb; 30(2):1745-1759. PubMed ID: 36826096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
    Cheah CY; Opat S; Trotman J; Marlton P
    Intern Med J; 2019 Sep; 49(9):1070-1080. PubMed ID: 30816618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical presentation and management of marginal zone lymphomas.
    Thieblemont C
    Hematology Am Soc Hematol Educ Program; 2005; ():307-13. PubMed ID: 16304396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy.
    Ayyappan S; William BM
    Curr Oncol Rep; 2018 Mar; 20(4):33. PubMed ID: 29572581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary management of nodal and primary splenic marginal zone lymphoma.
    Leslie LA; Feldman TA; McNeill A; Timberg M; Iida H; Goy AH
    Expert Rev Hematol; 2019 Dec; 12(12):1011-1022. PubMed ID: 31619091
    [No Abstract]   [Full Text] [Related]  

  • 6. Marginal Zone Lymphoma: State-of-the-Art Treatment.
    Sindel A; Al-Juhaishi T; Yazbeck V
    Curr Treat Options Oncol; 2019 Dec; 20(12):90. PubMed ID: 31807935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Treatments in Marginal Zone Lymphoma.
    Alderuccio JP; Kahl BS
    Oncology (Williston Park); 2022 Apr; 36(4):206-215. PubMed ID: 35436062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.
    Arcaini L; Paulli M; Boveri E; Vallisa D; Bernuzzi P; Orlandi E; Incardona P; Brusamolino E; Passamonti F; Burcheri S; Schena C; Pascutto C; Cavanna L; Magrini U; Lazzarino M
    Cancer; 2004 Jan; 100(1):107-15. PubMed ID: 14692030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
    Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C
    BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marginal zone B-cell lymphomas.
    Sagaert X; Tousseyn T
    Discov Med; 2010 Jul; 10(50):79-86. PubMed ID: 20670602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.
    Joshi M; Sheikh H; Abbi K; Long S; Sharma K; Tulchinsky M; Epner E
    Ther Adv Hematol; 2012 Oct; 3(5):275-90. PubMed ID: 23616915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
    Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
    Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective management strategies for patients with marginal zone lymphoma.
    Rosand CB; Valla K; Flowers CR; Koff JL
    Future Oncol; 2018 May; 14(12):1213-1222. PubMed ID: 29260925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project.
    Nathwani BN; Anderson JR; Armitage JO; Cavalli F; Diebold J; Drachenberg MR; Harris NL; MacLennan KA; Müller-Hermelink HK; Ullrich FA; Weisenburger DD
    J Clin Oncol; 1999 Aug; 17(8):2486-92. PubMed ID: 10561313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marginal zone B-cell lymphoma: lessons from Western and Eastern diagnostic approaches.
    Nakamura S; Ponzoni M
    Pathology; 2020 Jan; 52(1):15-29. PubMed ID: 31757436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma.
    Metcalf RA; Monabati A; Vyas M; Roncador G; Gualco G; Bacchi CE; Younes SF; Natkunam Y; Freud AG
    Hum Pathol; 2014 Aug; 45(8):1730-6. PubMed ID: 24925224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marginal zone lymphomas.
    Zucca E; Rossi D; Bertoni F
    Hematol Oncol; 2023 Jun; 41 Suppl 1():88-91. PubMed ID: 37294969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary nodal marginal zone lymphomas of splenic and MALT type.
    Campo E; Miquel R; Krenacs L; Sorbara L; Raffeld M; Jaffe ES
    Am J Surg Pathol; 1999 Jan; 23(1):59-68. PubMed ID: 9888704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transformation of marginal zone lymphoma (and association with other lymphomas).
    Casulo C; Friedberg J
    Best Pract Res Clin Haematol; 2017; 30(1-2):131-138. PubMed ID: 28288708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of marginal zone lymphomas.
    Thieblemont C; Coiffier B
    Curr Treat Options Oncol; 2006 May; 7(3):213-22. PubMed ID: 16615877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.